Loading...
XNAS
ADVM
Market cap58mUSD
Jun 10, Last price  
2.79USD
1D
-6.06%
1Q
-42.36%
Jan 2017
-90.38%
IPO
-98.89%
Name

Adverum Biotechnologies Inc

Chart & Performance

D1W1MN
P/E
—
P/S
16.19
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-30.32%
Rev. gr., 5y
17.43%
Revenues
4m
30,000480,000572,0002,319,0001,455,0001,849,0001,612,000250,00007,500,00003,600,000
Net income
-117m
L-24.18%
-1,811,000-5,276,000-25,404,000-47,453,000-113,747,000-56,147,000-72,627,000-64,486,000-117,507,000-145,540,000-154,536,000-117,165,000
CFO
-91m
L-15.90%
-1,267,000-2,175,000-5,648,000-35,338,000-38,366,000-45,421,000-53,964,000-49,170,000-79,291,000-107,831,000-108,091,000-90,902,000
Earnings
Aug 11, 2025

Profile

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
URL
https://adverum.com/
IPO date
Jul 31, 2014
Employees
123
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,600
 
Cost of revenue
133,235
163,663
Unusual Expense (Income)
NOPBT
(129,635)
(163,663)
NOPBT Margin
Operating Taxes
(1,078)
74
Tax Rate
NOPAT
(128,557)
(163,737)
Net income
(117,165)
-24.18%
(154,536)
6.18%
Dividends
Dividend yield
Proceeds from repurchase of equity
489
3
BB yield
-0.64%
-0.01%
Debt
Debt current
20,818
13,241
Long-term debt
139,663
200,363
Deferred revenue
Other long-term liabilities
1,047
Net debt
61,979
25,512
Cash flow
Cash from operating activities
(90,902)
(108,091)
CAPEX
(808)
(11,816)
Cash from investing activities
96,875
141,720
Cash from financing activities
69
607
FCF
(90,065)
(158,538)
Balance
Cash
96,526
185,589
Long term investments
1,976
2,503
Excess cash
98,322
188,092
Stockholders' equity
(920,240)
(804,133)
Invested Capital
1,095,241
1,093,246
ROIC
ROCE
EV
Common stock shares outstanding
10,082
9,925
Price
7.53
29.91%
5.80
-67.07%
Market cap
75,900
31.96%
57,516
-66.67%
EV
137,879
83,028
EBITDA
(123,991)
(157,135)
EV/EBITDA
Interest
2,673
Interest/NOPBT